Skip to main content

and
  1. Article

    Open Access

    Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

    The use of imatinib, an ABL tyrosine kinase inhibitor, has led to a dramatic change in the management of BCR-ABL-positive leukemia patients. However, resistance to imatinib mediated by mutations in the BCR-ABL...

    Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Shinya Kimura in Cancer Cell International (2013)